Reuters logo
BRIEF-FDA accepts for priority review Bristol-Myers Squibb's application for sprycel
July 10, 2017 / 11:21 AM / 4 months ago

BRIEF-FDA accepts for priority review Bristol-Myers Squibb's application for sprycel

July 10 (Reuters) - Bristol-Myers Squibb Co:

* U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb’s application for sprycel (dasatinib) in children with philadelphia chromosome-positive chronic phase chronic myeloid leukemia

* U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb’s application for sprycel (dasatinib) in children with philadelphia chromosome-positive chronic phase chronic myeloid leukemia

* Bristol-Myers Squibb Co - ‍submission includes powder for oral suspension formulation​

* Bristol-Myers Squibb Co- ‍application is under priority review with an action date of November 9, 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below